In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst Pharmaceuticals, Incyte presents 24-week results from the Phase III TRuE-AD4 trial of Opzelura, and Pharmaceutical Executive speaks with Charlie Lyon of the API Innovation Center on what the conversation about bringing pharmaceutical manufacturing back to the United States is still missing.
In today's Pharmaceutical Executive Daily, Bayer agrees to acquire Perfuse Therapeutics for up to $2.45 billion and Madrigal obtains an exclusive global license for a precision siRNA therapy targeting a key genetic driver of MASH, Zentalis Pharmaceuticals announces the first patient dosed in a Phase III trial and Brooke Ervin argues that translating real-world evidence into commercial and clinical impact in urology requires more than access to data.
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech releases its first quarter 2026 financial results, and Peter Harbin argues that biopharma's longstanding deciling-based sales targeting model is overdue for a fundamental rethink.
In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentary by Jeremy Richardson argues that MFN pricing and shifting policy expectations are making affordable direct-to-patient programs at scale an operational necessity rather than a strategic option, and a new article examines how a customer-based process can synchronize sales and marketing organizations for competitive advantage in pharma.
In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk profile for AstraZeneca's Truqap, FDA approves Axsome Therapeutics' Auvelity, and Pharmaceutical Executive speaks with Jeff Golfman on how global disruptions are cascading through the pharmaceutical supply chain.
In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US prescription drug spending is projected to surpass $1 trillion in 2026, and Inizio launches a next-generation hub services model aimed at simplifying patient access and support.
In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher, Teva Pharmaceutical enters a definitive agreement to acquire Emalex Biosciences for up to $900 million, and a feature article examines the pharmaceutical supply chain risks converging around the Strait of Hormuz.
In today's Pharmaceutical Executive Daily, we cover Sun Pharma and IMG Pharma's respective acquisitions, FDA's approval of AstraZeneca's Breztri, and a new feature examining why Ireland has become one of the pharmaceutical industry's most strategically important global manufacturing hubs.
In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, adding a first-in-class JAK2 inhibitor for blood cancers to its expanding oncology pipeline, the FDA approves a supplemental application for Johnson and Johnson's Caplyta backed by Phase III data showing a 63% reduction in relapse risk in adults with schizophrenia, and Pharmaceutical Executive speaks with Maher Masoud, CEO of MaxCyte, on moving cell and gene therapies toward commercial scale.
In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to lower patient costs tied to its newly approved gene therapy, and the FDA approves Otarmeni for OTOF-related hearing loss.
In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructure increasingly dictate where innovation is developed, manufactured, and commercialized.
In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent receives an expanded pediatric indication in chronic spontaneous urticaria, and AbbVie announces a $195 million investment to build a new manufacturing campus in North Carolina.
In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weight management program, and a new report highlights which top-selling drugs are most at risk of supply shortages.
In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected first-quarter results, Pfizer works to reshape its leadership narrative as it approaches a major patent cliff, and a new industry perspective highlights why scaling artificial intelligence in pharma requires more than just advanced algorithms.
In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues an executive order to accelerate FDA reviews of psychedelic therapies, and Lilly’s oral weight loss pill sees strong early prescribing demand.
Model N’s Michael Grosberg breaks down the accelerated complexity, policy disruption, and data gaps testing manufacturer market access and revenue management strategies.
In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approval request, ICER and Verdant Research publish a new white paper examining the evolution and future of the FDA's accelerated approval pathway, and a new Pharmaceutical Executive commentary argues FDA's shift toward single-trial approval standards marks the beginning of a genuinely new era in data-driven drug development.
In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical in a deal worth up to $745 million, the FDA grants full approval to Filspari as the first and only approved treatment for focal segmental glomerulosclerosis, and Pharmaceutical Executive speaks with Deepak Prakash of Identiv on how RFID and real-time tracking are building operational visibility in clinical trials.
In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced melanoma, Regeneron and Telix Pharmaceuticals announce a radiopharmaceutical collaboration worth up to $2.1 billion, and Pharmaceutical Executive speaks with Matt Holms of Citeline on improving patient experience and real-world evidence integration in clinical trials.
In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large study identifies genetic predictors of GLP-1 weight loss efficacy and side effects, and Pharmaceutical Executive speaks with Phenomix CEO Mark Bagnall on the complex realities of GLP-1 usage that many patients don't anticipate.
Ken Banta and Andy Milligan explore how life sciences leaders can rebuild relevance, consistency, and trust in today's complex and cost-focused era of healthcare.
In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant bacterial threats, Roche and C4 Therapeutics expand their long-standing partnership into a new collaboration to develop degrader-antibody conjugates for oncology, and Pharmaceutical Executive profiles AstraZeneca CFO Aradhana Sarin on how she approaches the role as a strategic catalyst for growth.
In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ahead of the company's annual meeting, a Louisiana federal judge declines to block mail-order access to mifepristone while leaving open the possibility of a future ruling against it, and a Q&A examines how the pharmaceutical industry is navigating the compounding pressures of the Iran war and tariff uncertainty on global supply chains.
In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.
In today's Pharmaceutical Executive Daily, Neurocrine Biosciences agrees to acquire Soleno Therapeutics for $2.9 billion to gain Vykat XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, BioNTech announces it will close its Singapore vaccine manufacturing facility by February 2027 as declining Covid revenues drive a strategic pivot, and Pharmaceutical Executive examines two emerging frameworks that specialty drug manufacturers are using to protect patient access and benefit savings in a shifting payer environment.
In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported patented pharmaceuticals under Section 232, with significant carve-outs for companies that have struck MFN pricing deals or committed to domestic manufacturing, Pfizer and BioNTech halt a large post-marketing Covid-19 vaccine trial in healthy adults aged 50 to 64 after failing to hit enrollment targets, and a new analysis examines how the industry is adapting strategically to a fundamentally transformed U.S. pricing environment.
In Part 2 of our podcast video episode with ZS CEO Pratap Khedkar, he breaks down pharma's need to move beyond AI pilots to scalable impact—and how companies can "go from informing to solving" while navigating trust, regulation, and a rapidly shifting patient dynamic.
In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump administration, Shionogi enters a $2 billion agreement to acquire rights to Radicava, and the FTC examines antitrust concerns tied to CVS Health’s integrated healthcare model.
In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK Jr.'s vaccine policy overhaul as political pressures mount ahead of the midterm elections, Biogen agrees to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, and Pharmaceutical Executive examines the risk-reward calculus facing R&D leaders in today's volatile development environment.
In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy targeting cash-paying patients through telehealth partners, Merck enters an $838 million research collaboration with antibody discovery startup Infinimmune, and Eli Lilly agrees to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion to expand into sleep-wake disorder treatments.
